Changjiang Pharmaceutical Group Co., Ltd.

As of June 30, 2025, Changjiang Pharmaceutical Group Co., Ltd. has 350.34M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 14.20, and the price-to-book ratio stands at -1.14.

These figures are as of June 30, 2025. The EV/Sales ratio of 19.89 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Changjiang Pharmaceutical Group Co., Ltd. trades at an EV/FCF ratio of 24.34, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2025, Changjiang Pharmaceutical Group Co., Ltd. maintains a current ratio of 0.53, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -113.92, indicating conservative leverage, while an interest coverage ratio of -1.56 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2025. Return on assets (ROA) is negative at -23.20, reflecting losses generated across the asset base. Inventory turnover of 2.13 indicates how many times Changjiang Pharmaceutical Group Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on April 10, 2026, Changjiang Pharmaceutical Group Co., Ltd.'s stock has declined approximately 96.01% over the past 52 weeks. The 50-day moving average sits at 0.74, while the 200-day moving average is 2.66.

Over the twelve months ended June 30, 2025, Changjiang Pharmaceutical Group Co., Ltd. posted a gross margin of -8.07, reflecting its pricing power and cost economics. The operating margin of -126.81 and net profit margin of -545.15 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. The dividend payout ratio of -1.01 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -0.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.90, meaning Changjiang Pharmaceutical Group Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Changjiang Pharmaceutical Group Co., Ltd.'s most recent stock split took place on May 10, 2019 with a 2:3 split ratio.

As of June 30, 2025, Changjiang Pharmaceutical Group Co., Ltd. has an Altman Z-Score of -1.71, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.